ST Pharm looks to expand oligo CDMO contracts at CPHI

[Financial News] ST Pharm is seeking to expand its oligonucleotide contract development and manufacturing (CDMO) business at CPHI Worldwide 2026, the world’s largest pharmaceutical trade show.
ST Pharm said on the 8th that it is participating in CPHI Worldwide 2026, being held in Milan, Italy, from the 6th through the 8th (local time), and holding business meetings with global pharmaceutical and biotech companies. The company plans to strengthen ties with existing clients while seeking out new projects.
A key factor this year is the expansion of production capacity as the second oligonucleotide facility, completed last year, begins full-scale operations. Equipped with production lines ranging from small and medium-sized to large, the facility can meet production needs of various scales, from early clinical stages through commercialization.
Leveraging its expanded production capacity and the quality competitiveness it has built up in global markets, ST Pharm is broadening collaboration with existing clients while focusing on securing new customers and projects.
At CPHI, ST Pharm is also meeting with clients for small-molecule active pharmaceutical ingredients (APIs), in addition to oligonucleotide clients, to review ongoing projects and discuss the potential for new business and expanded collaboration.
Since 2016, ST Pharm has expanded its engagement with global pharmaceutical and biotech companies by setting up a dedicated booth at CPHI every year alongside Dong-A ST Co., Ltd.
An ST Pharm representative said, “At this CPHI, we are showcasing ST Pharm’s oligonucleotide CDMO production capabilities and global competitiveness,” adding, “Building on our RNA-based technology and CDMO capabilities, we will strengthen collaboration with existing global partners and expand opportunities for new business.”

[email protected] Sang-hee Jeong Reporter